ocugen_4C_LOGO (002).png
Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
June 21, 2022 07:00 ET | Ocugen
Ocugen’s partner Bharat Biotech’s Phase 2/3 study of COVAXIN™ (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults Ocugen has North American...
ocugen_4C_LOGO (002).png
Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’
June 14, 2022 07:00 ET | Ocugen
MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies,...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy
June 13, 2022 07:00 ET | Ocugen
MALVERN, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell...
ocugen_4C_LOGO (002).png
Ocugen, Inc. to Present at BIO International Convention 2022
June 09, 2022 18:17 ET | Ocugen
MALVERN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and...
ocugen_4C_LOGO (002).png
Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition
May 24, 2022 07:11 ET | Ocugen
NeoCart® (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative medicines MALVERN, Pa., May 24, 2022 (GLOBE...
ocugen_4C_LOGO (002).png
Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference
May 23, 2022 07:34 ET | Ocugen
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and...
ocugen_4C_LOGO (002).png
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)
May 23, 2022 06:36 ET | Ocugen
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and...
ocugen_4C_LOGO (002).png
Ocugen Provides Business Update and First Quarter 2022 Financial Results
May 06, 2022 06:33 ET | Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is...
ocugen_4C_LOGO (002).png
Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results
May 02, 2022 07:37 ET | Ocugen
MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and...
ocugen_4C_LOGO (002).png
Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
April 29, 2022 11:36 ET | Ocugen
MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and...